| Ticker Symbol: | IOMI |
|---|---|
| Exchange: | NASD |
| Contact Info: | 20 Firstfield Road Gaithersburg MD 20878 301-556-4500 |
| CEO/President: | |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | Iomai Corporation is pioneering the delivery to the skin of potent biological molecules for vaccination and immuno-modulation that will prevent or treat a broad range of diseases. Transcutaneous immunization, developed at Walter Reed Army Institute of Research, is licensed exclusively to Iomai Corporation. Transcutaneous immunization is its proprietary platform for the development of the next generation of vaccines that will replace the needle and syringe and, it believes that it will result in more effective prevention and treatment of disease. |
| Shares Outstanding: | 25,590 (000) | Market Value: | 167,940 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 21.02% | Number of Inst.Shareholders: | N/A% |
| Last Quarter Sales: | 1.84 ($Mil.) | Last Quarter Net Income: | -6.50 ($Mil.) |
| Last Quarter EPS: | -0.25 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -1.00 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN | +41.90 | 64.08 | |
| GILEAD SCIENCES | +37.60 | 53.21 | |
| AMYLIN PHARMA I | -56.00 | 21.88 | |
| BIOGEN IDEC INC | -12.60 | 51.33 | |
| GENENTECH INC | +43.40 | 98.45 |
